75 and older, any sex, with Aging or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Intervention Efficacy for High Dose : Global Cognitive Function as Calculated From the Change From Baseline to Month 6Primary· Change from baseline to month 6
Global cognitive function measured by the Montreal Cognitive Assessment total score (MoCA total score). Montreal Cognitive Assessment is a neuropsychological test. Total score ranges from 0 to 30. Higher scores indicate better cognitive function.
Pre-pandemic cohort MoCA
Group
Value
95% CI
Conversational Engagement (NC)
0.40
± 2.27
Control Group (NC)
0.07
± 2.34
Conversational Engagement (MCI)
1.46
± 2.11
Control Group (MCI)
-0.44
± 2.04
Pre- and post-pandemic combined cohorts combined
Group
Value
95% CI
Conversational Engagement (NC)
-0.28
± 2.30
Control Group (NC)
0.31
± 2.25
Conversational Engagement (MCI)
1.37
± 3.04
Control Group (MCI)
0.22
± 2.33
Intervention Efficacy for High Dose: Language-based Executive FunctionSecondary· Change from baseline to month 6
Cognitive function in language-based executive function measured by Verbal Fluency Animal test. Verbal fluency Animals test is a neuropsychological test. In the test, participants have to produce as many words as possible from a category of animals within 60 seconds. Total score ranges from 0 to 70. Higher scores indicate better cognitive function.
Group
Value
95% CI
Conversational Engagement (NC)
1.06
± 4.24
Control Group (NC)
-0.46
± 4.30
Conversational Engagement (MCI)
-0.42
± 3.96
Control Group (MCI)
-0.59
± 4.11
Intervention Efficacy for High Dose: Learning FunctionSecondary· Change from baseline to month 6
Cognitive function in a learning domain (immediate recall) measured by Craft Story Immediate Recall test (paraphrase scoring). Craft Story Immediate Recall test (paraphrase scoring) is a neuropsychological test. Total score ranges from 0 to 25. Higher scores indicate better cognitive function. Scores reported are the mean change in score.
Group
Value
95% CI
Conversational Engagement (NC)
-.58
± 3.58
Control Group (NC)
.63
± 3.45
Conversational Engagement (MCI)
.73
± 3.51
Control Group (MCI)
.95
± 3.76
Intervention Efficacy for High Dose: Memory FunctionSecondary· Change from baseline to month 6
Cognitive function in a memory domain measured by Craft Story Delayed Recall test scores (paraphrase scoring). Craft Story Delayed Recall test (paraphrase scoring) is a neuropsychological test. Total score ranges from 0 to 25. Higher scores indicate better cognitive function. Scores are reported as a change score.
Group
Value
95% CI
Conversational Engagement (NC)
-.26
± 3.88
Control Group (NC)
.74
± 3.37
Conversational Engagement (MCI)
1.48
± 4.47
Control Group (MCI)
1.08
± 3.56
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected over 2 years, from baseline to follow-up..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The study aims to randomize 320 (160 Caucasian, 160 African American) socially isolated adults 75+ years old (50:50 split between those with normal cognition and mild cognitive impairment (MCI)) recruited from the community to either the Video Chat Group or the Control Group. The participants in the Video Chat Group will receive a computer and internet service for the duration of the study, which they will use to video chat with study staff for 30 minutes/day 4x/week for 6 months (high dose), and then 2x/week for an additional 6 months (maintenance dose). The efficacy examination of the maintenance dose is limited to an exploratory aim. Both intervention and control groups will have a brief (about 10 minutes) telephone check-in with study staff once per week. In-home testing will occur at Baseline and 6 months. A sub-sample of participants\*\* will be assessed at 12 months (exploratory) after additional 6 months of maintenance dose. All participants at OHSU will have their medication compliance tracked using an electronic medication monitoring device and participants at both OHSU and UM will have MRIs at Baseline and 6 months, if they are able to safely receive MRIs. Participants at both sites will contribute saliva for genetic testing (optional consent), and all video chat and neuropsychological assessment sessions will be recorded for speech and language analysis (consent required for participation).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI
· recruiting
NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
· recruiting
NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in
· NA
· recruiting
NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults
· NA
· recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS
· NA
· recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
· withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg
· NA
· not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior
· NA
· not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries
· NA
· not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02871921.